U Hamid1, A Krasnodembskaya1, M Fitzgerald1, M Shyamsundar1, A Kissenpfennig1, C Scott2, E Lefrancais3, M R Looney3, R Verghis4, J Scott5, A J Simpson5, J McNamee6, D F McAuley1,6, C M O'Kane1. 1. Centre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, Northern Ireland, UK. 2. School of Pharmacy, Queen's University of Belfast, Belfast, Northern Ireland, UK. 3. Department of Medicine, University of California San Francisco, San Francisco, California, USA. 4. Northern Ireland Clinical Trials Unit, Royal Victoria Hospital, Belfast, UK. 5. Institute of Cellular Medicine, Medical School, Newcastle University, Newcastle-upon Tyne, UK. 6. Regional Intensive Care Unit, Royal Victoria Hospital, Belfast Health and Social Care Trust, Belfast, UK.
Abstract
RATIONALE: Platelets play an active role in the pathogenesis of acute respiratory distress syndrome (ARDS). Animal and observational studies have shown aspirin's antiplatelet and immunomodulatory effects may be beneficial in ARDS. OBJECTIVE: To test the hypothesis that aspirin reduces inflammation in clinically relevant human models that recapitulate pathophysiological mechanisms implicated in the development of ARDS. METHODS:Healthy volunteers were randomised to receive placebo or aspirin 75 or 1200 mg (1:1:1) for seven days prior to lipopolysaccharide (LPS) inhalation, in a double-blind, placebo-controlled, allocation-concealed study. Bronchoalveolar lavage (BAL) was performed 6 hours after inhaling 50 µg of LPS. The primary outcome measure was BAL IL-8. Secondary outcome measures included markers of alveolar inflammation (BAL neutrophils, cytokines, neutrophil proteases), alveolar epithelial cell injury, systemic inflammation (neutrophils and plasma C-reactive protein (CRP)) and platelet activation (thromboxane B2, TXB2). Human lungs, perfused and ventilated ex vivo (EVLP) were randomised to placebo or 24 mg aspirin and injured with LPS. BAL was carried out 4 hours later. Inflammation was assessed by BAL differential cell counts and histological changes. RESULTS: In the healthy volunteer (n=33) model, data for the aspirin groups were combined. Aspirin did not reduce BAL IL-8. However, aspirin reduced pulmonary neutrophilia and tissue damaging neutrophil proteases (Matrix Metalloproteinase (MMP)-8/-9), reduced BAL concentrations of tumour necrosis factor α and reduced systemic and pulmonary TXB2. There was no difference between high-dose and low-dose aspirin. In the EVLP model, aspirin reduced BAL neutrophilia and alveolar injury as measured by histological damage. CONCLUSIONS: These are the first prospective human data indicating that aspirin inhibits pulmonary neutrophilic inflammation, at both low and high doses. Further clinical studies are indicated to assess the role of aspirin in the prevention and treatment of ARDS. TRIAL REGISTRATION NUMBER: NCT01659307 Results. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
RCT Entities:
RATIONALE: Platelets play an active role in the pathogenesis of acute respiratory distress syndrome (ARDS). Animal and observational studies have shown aspirin's antiplatelet and immunomodulatory effects may be beneficial in ARDS. OBJECTIVE: To test the hypothesis that aspirin reduces inflammation in clinically relevant human models that recapitulate pathophysiological mechanisms implicated in the development of ARDS. METHODS: Healthy volunteers were randomised to receive placebo or aspirin 75 or 1200 mg (1:1:1) for seven days prior to lipopolysaccharide (LPS) inhalation, in a double-blind, placebo-controlled, allocation-concealed study. Bronchoalveolar lavage (BAL) was performed 6 hours after inhaling 50 µg of LPS. The primary outcome measure was BAL IL-8. Secondary outcome measures included markers of alveolar inflammation (BAL neutrophils, cytokines, neutrophil proteases), alveolar epithelial cell injury, systemic inflammation (neutrophils and plasma C-reactive protein (CRP)) and platelet activation (thromboxane B2, TXB2). Human lungs, perfused and ventilated ex vivo (EVLP) were randomised to placebo or 24 mg aspirin and injured with LPS. BAL was carried out 4 hours later. Inflammation was assessed by BAL differential cell counts and histological changes. RESULTS: In the healthy volunteer (n=33) model, data for the aspirin groups were combined. Aspirin did not reduce BAL IL-8. However, aspirin reduced pulmonary neutrophilia and tissue damaging neutrophil proteases (Matrix Metalloproteinase (MMP)-8/-9), reduced BAL concentrations of tumour necrosis factor α and reduced systemic and pulmonary TXB2. There was no difference between high-dose and low-dose aspirin. In the EVLP model, aspirin reduced BAL neutrophilia and alveolar injury as measured by histological damage. CONCLUSIONS: These are the first prospective human data indicating that aspirin inhibits pulmonary neutrophilic inflammation, at both low and high doses. Further clinical studies are indicated to assess the role of aspirin in the prevention and treatment of ARDS. TRIAL REGISTRATION NUMBER: NCT01659307 Results. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Jochen Grommes; Jean-Eric Alard; Maik Drechsler; Sarawuth Wantha; Matthias Mörgelin; Wolfgang M Kuebler; Michael Jacobs; Philipp von Hundelshausen; Philipp Markart; Malgorzata Wygrecka; Klaus T Preissner; Tilman M Hackeng; Rory R Koenen; Christian Weber; Oliver Soehnlein Journal: Am J Respir Crit Care Med Date: 2012-01-12 Impact factor: 21.405
Authors: Axelle Caudrillier; Kai Kessenbrock; Brian M Gilliss; John X Nguyen; Marisa B Marques; Marc Monestier; Pearl Toy; Zena Werb; Mark R Looney Journal: J Clin Invest Date: 2012-06-11 Impact factor: 14.808
Authors: David M Sayah; Beñat Mallavia; Fengchun Liu; Guadalupe Ortiz-Muñoz; Axelle Caudrillier; Ariss DerHovanessian; David J Ross; Joseph P Lynch; Rajan Saggar; Abbas Ardehali; Lorraine B Ware; Jason D Christie; John A Belperio; Mark R Looney Journal: Am J Respir Crit Care Med Date: 2015-02-15 Impact factor: 21.405
Authors: Murali Shyamsundar; Scott T W McKeown; Cecilia M O'Kane; Thelma R Craig; Vanessa Brown; David R Thickett; Michael A Matthay; Clifford C Taggart; Janne T Backman; J Stuart Elborn; Daniel F McAuley Journal: Am J Respir Crit Care Med Date: 2009-03-26 Impact factor: 21.405
Authors: Jeffrey N Harr; Ernest E Moore; Jeffrey Johnson; Theresa L Chin; Max V Wohlauer; Ronald Maier; Joseph Cuschieri; Jason Sperry; Anirban Banerjee; Christopher C Silliman; Angela Sauaia Journal: Crit Care Med Date: 2013-02 Impact factor: 7.598
Authors: D F McAuley; G F Curley; U I Hamid; J G Laffey; J Abbott; D H McKenna; X Fang; M A Matthay; J W Lee Journal: Am J Physiol Lung Cell Mol Physiol Date: 2014-02-14 Impact factor: 5.464
Authors: Shaun Spence; Michelle K Greene; François Fay; Emily Hams; Sean P Saunders; Umar Hamid; Marianne Fitzgerald; Jonathan Beck; Baljinder K Bains; Peter Smyth; Efrosyni Themistou; Donna M Small; Daniela Schmid; Cecilia M O'Kane; Denise C Fitzgerald; Sharif M Abdelghany; James A Johnston; Padraic G Fallon; James F Burrows; Daniel F McAuley; Adrien Kissenpfennig; Christopher J Scott Journal: Sci Transl Med Date: 2015-09-02 Impact factor: 17.956
Authors: Elizabeth A Middleton; Matthew T Rondina; Hansjorg Schwertz; Guy A Zimmerman Journal: Am J Respir Cell Mol Biol Date: 2018-07 Impact factor: 6.914
Authors: Ashraf Fawzy; Nirupama Putcha; Carrie P Aaron; Russell P Bowler; Alejandro P Comellas; Christopher B Cooper; Mark T Dransfield; MeiLan K Han; Eric A Hoffman; Richard E Kanner; Jerry A Krishnan; Wassim W Labaki; Robert Paine; Laura M Paulin; Stephen P Peters; Robert Wise; R Graham Barr; Nadia N Hansel Journal: Chest Date: 2018-12-26 Impact factor: 9.410
Authors: Siân Lax; Julie Rayes; Surasak Wichaiyo; Elizabeth J Haining; Kate Lowe; Beata Grygielska; Ryan Laloo; Per Flodby; Zea Borok; Edward D Crandall; David R Thickett; Steve P Watson Journal: Am J Physiol Lung Cell Mol Physiol Date: 2017-08-24 Impact factor: 5.464
Authors: Damon P Eisen; Karin Leder; Robyn L Woods; Jessica E Lockery; Sarah L McGuinness; Rory Wolfe; David Pilcher; Elizabeth M Moore; Adithya Shastry; Mark R Nelson; Christopher M Reid; John J McNeil; Emma S McBryde Journal: Lancet Respir Med Date: 2020-09-17 Impact factor: 30.700